Abstract
The design of selective COX-2 inhibitors is a new approach to obtain potent, anti-inflammatory drugs but with less side effects. Several families of such inhibitors were reported in literature. In this review, the drug design processes used to understand their binding mode and the origin of selectivity of these compounds are described.
Keywords: cox-2 inhibitor, selectivity, molecular modelling, x-ray, drug design, cox binding site, molecular features
Mini-Reviews in Medicinal Chemistry
Title: Structural Approach for COX-2 Inhibition
Volume: 4 Issue: 6
Author(s): C. Michaux and C. Charlier
Affiliation:
Keywords: cox-2 inhibitor, selectivity, molecular modelling, x-ray, drug design, cox binding site, molecular features
Abstract: The design of selective COX-2 inhibitors is a new approach to obtain potent, anti-inflammatory drugs but with less side effects. Several families of such inhibitors were reported in literature. In this review, the drug design processes used to understand their binding mode and the origin of selectivity of these compounds are described.
Export Options
About this article
Cite this article as:
Michaux C. and Charlier C., Structural Approach for COX-2 Inhibition, Mini-Reviews in Medicinal Chemistry 2004; 4 (6) . https://dx.doi.org/10.2174/1389557043403756
DOI https://dx.doi.org/10.2174/1389557043403756 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antioxidant and ‘Natural Protective’ Properties of Kiwifruit
Current Topics in Medicinal Chemistry Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Nicotine Addiction and Coronary Artery Disease: Impact of Cessation Interventions
Current Pharmaceutical Design The Blood-Brain Barrier as a Cause of Obesity
Current Pharmaceutical Design Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication
Anti-Cancer Agents in Medicinal Chemistry Silver and Other Metals in the Treatment of Gastrointestinal Diseases
Current Medicinal Chemistry The Toll of Toll-Like Receptors, Especially Toll-Like Receptor 2, on Murine Atherosclerosis
Current Drug Targets Current and Next Generation Topical Anti-Skin Cancer Therapeutics
Drug Delivery Letters Repressing the Activity of Protein Kinase CK2 Releases Mitochondria-Mediated Apoptosis in Cancer Cells
Current Drug Targets Topical Delivery of Antioxidants
Current Drug Delivery Association of Cytokine Gene Polymorphisms (IL6, IL10, TNF-α, TGF-β and IFN-γ) and Graves’ Disease in Turkish Population
Endocrine, Metabolic & Immune Disorders - Drug Targets The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry Inflammatory Mechanisms of Adverse Reactions to BMS
Current Vascular Pharmacology Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology The Immune Diversity in a Test Tube - Non-Immunised Antibody Libraries and Functional Variability in Defined Protein Scaffolds
Combinatorial Chemistry & High Throughput Screening Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) LYP3, a New Bestatin Derivative for Aminopeptidase N Inhibition
Medicinal Chemistry The Chemistry of Epoxy Alcohols
Current Organic Chemistry Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors
Letters in Drug Design & Discovery